Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance

No abstract is available for this paper.

• Publication year

  2004

• Venue

  International Journal of Gynecologic Cancer

• Publication date

  2004-06-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ijgc-00009577-200503000-00004PMID 15823101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of704 patients

  2005cited by this paper
• Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

  2004cited by this paper
• Sialometrical and Sialochemical Analysis of Patients with Chronic Graft-Versus-Host Disease—A Prolonged Study

  2003cited by this paper
• Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?

  2001cited by this paper
• Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

  2001cited by this paper
• Evidence that a “treatment-free interval of less than 6 months” does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma

  1998cited by this paper
• "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?

  1998cited by this paper
• Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].

  1997cited by this paper
• Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

  1996cited by this paper
• Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.

  1995cited by this paper
• Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

  1991cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Re-Treatment of Patients With Recurrent Epithelial Ovarian Cancer With Cisplatin-Based Chemotherapy

  1989cited by this paper

• Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study.

  2025cites this paper
• Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.

  2025cites this paper
• Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer

  2023cites this paper
• CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

  2023cites this paper
• The role of DNA methylation in ovarian cancer chemoresistance: A narrative review

  2023cites this paper
• Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.

  2022cites this paper
• ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.

  2022cites this paper
• An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer

  2022cites this paper
• Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer

  2018cites this paper
• Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

  2017cites this paper
• Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.

  2017cites this paper
• Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.

  2017influential citation
• Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

  2017cites this paper
• Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.

  2016cites this paper
• Using Epigenetic Therapy to Overcome Chemotherapy Resistance.

  2016cites this paper
• Epigenetic Targeting of Platinum Resistant Testicular Cancer.

  2016cites this paper
• Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

  2015cites this paper
• Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

  2014cites this paper
• Rewriting the Epigenetic Code for Tumor Resensitization: A Review

  2014cites this paper
• Ovarian Cancer: BRCA Genetics Reveals Targets for New Therapies

  2014cites this paper
• Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

  2013cites this paper
• Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.

  2013cites this paper
• Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

  2012cites this paper
• Epigenetic resensitization to platinum in ovarian cancer.

  2012cites this paper
• Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.

  2012cites this paper
• From amino acids to proteins as targets for metal-based drugs.

  2012cites this paper
• Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.

  2012cites this paper
• Chemotherapeutic management of recurrent ovarian cancer

  2012cites this paper
• Catalytic Electrochemical Analysis of Platinum in Pt-DNA Adducts

  2012cites this paper
• Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

  2012cites this paper
• Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis?

  2011cites this paper
• Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

  2011cites this paper
• Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer

  2011cites this paper
• Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

  2011influential citation
• Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer

  2011cites this paper
• Recurrent Ovarian Cancer: When and How to Treat

  2011cites this paper
• ' s response to reviews Title : Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy : A tangible union against chemoresistant cancer

  2011cites this paper
• Overcoming platinum resistance in ovarian carcinoma

  2010influential citation
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

  2010cites this paper
• Automated Electrochemical Analyzer as a New Tool for Detection of Thiols

  2010cites this paper
• Chemotherapy resistance and retreatment: a dogma revisited.

  2010cites this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

  2010cites this paper
• Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.

  2010cites this paper
• Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.

  2010cites this paper
• Management of partially platinum-sensitive relapsed ovarian cancer

  2008cites this paper
• Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?

  2008cites this paper
• Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer

  2007cites this paper
• A Suggestion of Electrochemical Biosensor for Study of Platinum(II)‐DNA Interactions

  2007cites this paper
• Aromatase inhibitors in ovarian cancer: is there a role?

  2007cites this paper
• Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

  2007cites this paper
• Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.

  2007cites this paper
• Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium.

  2006cites this paper
• Validation de facteurs potentiels de chimiorésistance du cancer de l'ovaire par immunohistochimie

  2006cites this paper